Advertisement

Endothelial Cells (ECs) Metabolism: A Valuable Piece to Disentangle Cancer Biology

  • Filipa Lopes-Coelho
  • Filipa Martins
  • Jacinta SerpaEmail author
Chapter
  • 208 Downloads
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1219)

Abstract

Effective therapies to fight cancer should not be focused specifically on cancer cells, but it should consider the various components of the TME. Non-cancerous cells cooperate with cancer cells by sharing signaling and organic molecules, accounting for cancer progression. Most of the anti-angiogenic therapy clinically approved for the treatment of human diseases relies on targeting vascular endothelial growth factor (VEGF) signaling pathway. Unexpectedly and unfortunately, the results of anti-angiogenic therapies in the treatment of human diseases are not so effective, showing an insufficient efficacy and resistance.

This chapter will give some insights on showing that targeting endothelial cell metabolism is a missing piece to revolutionize cancer therapy. Only recently endothelial cell (EC) metabolism has been granted as an important inducer of angiogenesis. Metabolic studies in EC demonstrated that targeting EC metabolism can be an alternative to overcome the failure of anti-angiogenic therapies. Hence, it is urgent to increase the knowledge on how ECs alter their metabolism during human diseases, in order to open new therapeutic perspectives in the treatment of pathophysiological angiogenesis, as in cancer.

Keywords

Metabolic remodeling Tumor microenvironment (TME) Angiogenesis Endothelial differentiation Cancer progression Cancer therapy 

Notes

Acknowledgments

The authors acknowledge iNOVA4Health – UID/Multi/04462/2013, a program financially supported by Fundação para a Ciência e Tecnologia/Ministério da Educação e Ciência, through national funds and co-funded by FEDER under the PT2020 Partnership Agreement.

References

  1. Adams RH, Alitalo K (2007) Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 8:464–478.  https://doi.org/10.1038/nrm2183CrossRefPubMedGoogle Scholar
  2. Amin DN, Hida K, Bielenberg DR, Klagsbrun M (2006) Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors. Cancer Res 66:2173–2180.  https://doi.org/10.1158/0008-5472.CAN-05-3387CrossRefPubMedGoogle Scholar
  3. Asthana A, Ramakrishnan P, Vicioso Y et al (2018) Hexosamine biosynthetic pathway inhibition leads to AML cell differentiation and cell death. Mol Cancer Ther 17:2226–2237.  https://doi.org/10.1158/1535-7163.mct-18-0426CrossRefPubMedPubMedCentralGoogle Scholar
  4. Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3:401–410.  https://doi.org/10.1038/nrc1093CrossRefPubMedGoogle Scholar
  5. Blanco R, Gerhardt H (2013) VEGF and notch in tip and stalk cell selection. Cold Spring Harb Perspect Med 3:1–19CrossRefGoogle Scholar
  6. Blecha J, Novais SM, Rohlenova K et al (2017) Antioxidant defense in quiescent cells determines selectivity of electron transport chain inhibition-induced cell death. Free Radic Biol Med 112:253–266.  https://doi.org/10.1016/j.freeradbiomed.2017.07.033CrossRefPubMedGoogle Scholar
  7. Bussolati B, Deambrosis I, Russo S et al (2003) Altered angiogenesis and survival in human tumor-derived endothelial cells. FASEB J 17:1159–1161CrossRefGoogle Scholar
  8. Cantelmo AR, Conradi LC, Brajic A et al (2016) Inhibition of the glycolytic activator PFKFB3 in endothelium induces tumor vessel normalization, impairs metastasis, and improves chemotherapy. Cancer Cell 30:968–985.  https://doi.org/10.1016/j.ccell.2016.10.006CrossRefPubMedPubMedCentralGoogle Scholar
  9. Cantelmo AR, Pircher A, Kalucka J, Carmeliet P (2017) Vessel pruning or healing: endothelial metabolism as a novel target? Expert Opin Ther Targets 21:239–247.  https://doi.org/10.1080/14728222.2017.1282465CrossRefPubMedPubMedCentralGoogle Scholar
  10. Carvalho-cruz P, Alisson-Silva F, Todeschini AR, Dias WB (2018) Cellular glycosylation senses metabolic changes and modulates cell plasticity during epithelial to mesenchymal transition. Dev Dyn 247:481–491.  https://doi.org/10.1002/dvdy.24553CrossRefPubMedGoogle Scholar
  11. Ceradini DJ, Kulkarni AR, Callaghan MJ et al (2004) Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 10:858–864.  https://doi.org/10.1038/nm1075CrossRefPubMedGoogle Scholar
  12. Chang YS, di Tomaso E, McDonald DM et al (2002) Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci 97:14608–14613.  https://doi.org/10.1073/pnas.97.26.14608CrossRefGoogle Scholar
  13. Chen L, Hou X, Xiao J et al (2014) Both hydrogen peroxide and transforming growth factor beta 1 contribute to endothelial Nox4 mediated angiogenesis in endothelial Nox4 transgenic mouse lines. Biochim Biophys Acta Mol basis Dis 1842:2489–2499.  https://doi.org/10.1016/j.bbadis.2014.10.007CrossRefGoogle Scholar
  14. Chiaradonna F, Ricciardiello F, Palorini R (2018) The nutrient-sensing Hexosamine biosynthetic pathway as the hub of Cancer metabolic rewiring. Cells 7:pii: E53.  https://doi.org/10.3390/cells7060053CrossRefGoogle Scholar
  15. Cho S (2012) CD36 as a therapeutic target for endothelial dysfunction in stroke. Curr Pharm Des 18:3721–3730.  https://doi.org/10.2174/138161212802002760CrossRefPubMedPubMedCentralGoogle Scholar
  16. Choi BH, Pagano M, Da W (2014) Plk1 protein phosphorylates phosphatase and tensin homolog (PTEN) and regulates its mitotic activity during the cell cycle. J Biol Chem 289:14066–14074.  https://doi.org/10.1074/jbc.M114.558155CrossRefPubMedPubMedCentralGoogle Scholar
  17. Ciccone V, Terzuoli E, Donnini S et al (2018) Stemness marker ALDH1A1 promotes tumor angiogenesis via retinoic acid/HIF-1α/VEGF signalling in MCF-7 breast cancer cells\. J Exp Clin Cancer Res 37:311.  https://doi.org/10.1186/s13046-018-0975-0CrossRefPubMedPubMedCentralGoogle Scholar
  18. Colavitti R, Pani G, Bedogni B et al (2002) Reactive oxygen species as downstream mediators of Angiogenic signaling by vascular endothelial growth factor Receptor-2/KDR. J Biol Chem 277:3101–3108.  https://doi.org/10.1074/jbc.M107711200CrossRefPubMedGoogle Scholar
  19. Conradi LC, Brajic A, Cantelmo AR et al (2017) Tumor vessel disintegration by maximum tolerable PFKFB3 blockade. Angiogenesis 20:599–613.  https://doi.org/10.1007/s10456-017-9573-6CrossRefPubMedGoogle Scholar
  20. Coso S, Harrison I, Harrison CB et al (2012) NADPH oxidases as regulators of tumor angiogenesis: current and emerging concepts. Antioxid Redox Signal 16:1229–1247.  https://doi.org/10.1089/ars.2011.4489CrossRefPubMedGoogle Scholar
  21. Coutelle O, Hornig-Do HT, Witt A et al (2014) Embelin inhibits endothelial mitochondrial respiration and impairs neoangiogenesis during tumor growth and wound healing. EMBO Mol Med 6:624–639.  https://doi.org/10.1002/emmm.201303016CrossRefPubMedPubMedCentralGoogle Scholar
  22. De Bock K, Georgiadou M, Schoors S et al (2013) Role of PFKFB3-driven glycolysis in vessel sprouting. Cell 154:651–663.  https://doi.org/10.1016/j.cell.2013.06.037CrossRefGoogle Scholar
  23. de Queiroz RM, Oliveira IA, Piva B et al (2019) Hexosamine biosynthetic pathway and glycosylation regulate cell migration in melanoma cells. Front Oncol 17:2226–2237.  https://doi.org/10.3389/fonc.2019.00116CrossRefGoogle Scholar
  24. DeBerardinis RJ, Cheng T (2010) Q’s next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 29:313–324.  https://doi.org/10.1038/onc.2009.358CrossRefPubMedGoogle Scholar
  25. DeClerck K (2010) The role of hypoxia and acidosis in promoting metastasis and resistance to chemotherapy. Front Biosci 15:213–225.  https://doi.org/10.2741/3616CrossRefGoogle Scholar
  26. Dewangan J, Srivastava S, Mishra S et al (2019) Salinomycin inhibits breast cancer progression via targeting HIF-1α/VEGF mediated tumorangiogenesis in vitro and in vivo. Biochem Pharmacol. pii:S0006-:30161–3Google Scholar
  27. Domingues G, Fernandes SG, Serpa J (2015) Chapter 3: Dynamics of VEGF-A and its receptors in Cancer vascularization – an overview In: Understand cancer: research and treatment. iConcept Press–ISBN 978-1-922227-386Google Scholar
  28. Don AS, Kisker O, Dilda P et al (2003) A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells. Cancer Cell 3:497–509.  https://doi.org/10.1016/S1535-6108(03)00109-0CrossRefPubMedGoogle Scholar
  29. Draoui N, De Zeeuw P, Carmeliet P (2017) Angiogenesis revisited from a metabolic perspective : role and therapeutic implications of endothelial cell metabolism. Open Biol 7(12). pii: 170219.  https://doi.org/10.1098/rsob.170219CrossRefGoogle Scholar
  30. Eelen G, de Zeeuw P, Simons M, Carmeliet P (2015) Endothelial cell metabolism in normal and diseased vasculature. Circ Res 116:1231–1244.  https://doi.org/10.1161/CIRCRESAHA.116.302855CrossRefPubMedPubMedCentralGoogle Scholar
  31. Eelen G, de Zeeuw P, Treps L et al (2018a) Endothelial cell metabolism. Physiol Rev 98:3–58.  https://doi.org/10.1152/physrev.00001.2017CrossRefPubMedPubMedCentralGoogle Scholar
  32. Eelen G, Dubois C, Cantelmo AR et al (2018b) Role of glutamine synthetase in angiogenesis beyond glutamine synthesis. Nature 561:63–69.  https://doi.org/10.1038/s41586-018-0466-7CrossRefGoogle Scholar
  33. Ehsanipour EA, Sheng X, Behan JW et al (2013) Adipocytes cause leukemia cell resistance to l-asparaginase via release of glutamine. Cancer Res 73:2998–3006.  https://doi.org/10.1158/0008-5472.CAN-12-4402CrossRefPubMedPubMedCentralGoogle Scholar
  34. Elmasri H, Karaaslan C, Teper Y et al (2009) Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells. FASEB J 23:3865–3873.  https://doi.org/10.1096/fj.09-134882CrossRefPubMedPubMedCentralGoogle Scholar
  35. Elmasri H, Ghelfi E, Yu CW et al (2012) Endothelial cell-fatty acid binding protein 4 promotes angiogenesis: role of stem cell factor/c-kit pathway. Angiogenesis 15:457–468.  https://doi.org/10.1007/s10456-012-9274-0CrossRefPubMedPubMedCentralGoogle Scholar
  36. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285(21):1182–1186CrossRefGoogle Scholar
  37. Gerbod-Giannone MC, Dallet L, Naudin G et al (2019) Involvement of caveolin-1 and CD36 in native LDL endocytosis by endothelial cells. Biochim Biophys Acta – Gen Subj 1863:830–838.  https://doi.org/10.1016/j.bbagen.2019.01.005CrossRefPubMedGoogle Scholar
  38. Ghesquière B, Wong BW, Kuchnio A, Carmeliet P (2014) Metabolism of stromal and immune cells in health and disease. Nature 511:167–176.  https://doi.org/10.1038/nature13312CrossRefGoogle Scholar
  39. Gimbrone MA, Leapman SB, Cotran RS, Folkman J (1972) Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 136:261–276CrossRefGoogle Scholar
  40. Goel HL, Mercurio AM (2013) VEGF targets the tumour cell. Nat Rev Cancer 13:871–882.  https://doi.org/10.1038/nrc3627CrossRefPubMedPubMedCentralGoogle Scholar
  41. Guo Y, Deng Y, Li X et al (2016) Glutaminolysis was induced by TGF-β1 through PP2Ac regulated Raf-MEK-ERK signaling in endothelial cells. PLoS One 11:e0162658.  https://doi.org/10.1371/journal.pone.0162658CrossRefPubMedPubMedCentralGoogle Scholar
  42. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674.  https://doi.org/10.1016/j.cell.2011.02.013CrossRefGoogle Scholar
  43. Hanover JA, Chen W, Bond MR (2018) O-GlcNAc in cancer: an Oncometabolism-fueled vicious cycle. J Bioenerg Biomembr 50:155–173.  https://doi.org/10.1007/s10863-018-9751-2CrossRefPubMedGoogle Scholar
  44. Hausenloy DJ, Yellon DM (2011) The therapeutic potential of ischemic conditioning: an update. Nat Rev Cardiol 8:619–629.  https://doi.org/10.1038/nrcardio.2011.85CrossRefPubMedGoogle Scholar
  45. Helfinger V, Henke N, Harenkamp S et al (2016) The NADPH oxidase Nox4 mediates tumour angiogenesis. Acta Physiol 216:435–446.  https://doi.org/10.1111/apha.12625CrossRefGoogle Scholar
  46. Helmlinger G, Endo M, Ferrara N et al (2002) Formation of endothelial cell networks. Nature 405:139–141.  https://doi.org/10.1038/35012132CrossRefGoogle Scholar
  47. Hilger RA, Scheulen ME, Strumberg D (2002) The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie 25:511–518.  https://doi.org/10.1159/000068621CrossRefPubMedGoogle Scholar
  48. Hillen F, Griffioen AW (2007) Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev 26:489–502.  https://doi.org/10.1007/s10555-007-9094-7CrossRefPubMedPubMedCentralGoogle Scholar
  49. Hinze L, Pfirrmann M, Karim S et al (2019) Synthetic lethality of Wnt pathway activation and asparaginase in drug-resistant acute leukemias. Cancer Cell 35:664–676.  https://doi.org/10.1016/j.ccell.2019.03.004CrossRefPubMedGoogle Scholar
  50. Huang Y-J, Nan G-X (2019) Oxidative stress-induced angiogenesis. J Clin Neurosci 63:13–16.  https://doi.org/10.1016/j.jocn.2019.02.019CrossRefPubMedGoogle Scholar
  51. Huang H, Vandekeere S, Kalucka J et al (2017) Role of glutamine and interlinked asparagine metabolism in vessel formation. EMBO J 36:2334–2352.  https://doi.org/10.15252/embj.201695518CrossRefPubMedPubMedCentralGoogle Scholar
  52. Hunt TK, Aslam RS, Beckert S et al (2007) Aerobically derived lactate stimulates revascularization and tissue repair via redox mechanisms. Antioxid Redox Signal 9:1115–1124.  https://doi.org/10.1089/ars.2007.1674CrossRefPubMedPubMedCentralGoogle Scholar
  53. Hunt TK, Aslam R, Hussain Z, Beckert S (2008) Lactate, with oxygen, incites angiogenesis. In: Advances in experimental medicine and Biology – in oxygen transport to tissue XXIX. Springer, New York, pp 73–80CrossRefGoogle Scholar
  54. Jain RK (2014) Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 26:605–622.  https://doi.org/10.1016/j.ccell.2014.10.006CrossRefPubMedPubMedCentralGoogle Scholar
  55. Jung S, Kleinheinz J (2013) Angiogenesis – the key to regeneration. In: Regenerative medicine and tissue engineering. IntechOpen, Rijeka, pp 453–473Google Scholar
  56. Kaczara P, Proniewski B, Lovejoy C et al (2018) CORM-401 induces calcium signalling, NO increase and activation of pentose phosphate pathway in endothelial cells. FEBS J 285:1346–1358.  https://doi.org/10.1111/febs.14411CrossRefPubMedGoogle Scholar
  57. Kim Y-W, Byzova TV (2014) Oxidative stress in angiogenesis and vascular disease. Blood 123:625–631.  https://doi.org/10.1182/blood-2013-09-512749CrossRefPubMedPubMedCentralGoogle Scholar
  58. Kim Y-W, West XZ, Byzova TV (2013) Inflammation and oxidative stress in angiogenesis and vascular disease. J Mol Med 91:323–328.  https://doi.org/10.1007/s00109-013-1007-3CrossRefPubMedPubMedCentralGoogle Scholar
  59. Kim B, Li J, Jang C, Arany Z (2017) Glutamine fuels proliferation but not migration of endothelial cells. EMBO J 36.  https://doi.org/10.15252/embj.201796436CrossRefGoogle Scholar
  60. Ko YH, Lin Z, Flomenberg N et al (2011) Glutamine fuels a vicious cycle of autophagy in the tumor stroma and oxidative mitochondrial metabolism in epithelial cancer cells: implications for preventing chemotherapy resistance. Cancer Biol Ther 12:1085–1097.  https://doi.org/10.4161/cbt.12.12.18671CrossRefPubMedPubMedCentralGoogle Scholar
  61. Kowanetz M, Ferrara N (2006) Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res 12:5018–5023.  https://doi.org/10.1158/1078-0432.CCR-06-1520CrossRefPubMedGoogle Scholar
  62. Kurosu T, Ohga N, Hida Y et al (2011) HuR keeps an angiogenic switch on by stabilising mRNA of VEGF and COX-2 in tumour endothelium. Br J Cancer 104:819–829.  https://doi.org/10.1038/bjc.2011.20CrossRefPubMedPubMedCentralGoogle Scholar
  63. Lee J, Kang S, Wang X et al (2019) HAP1 loss confers L-asparaginase resistance in ALL by downregulating the calpain-1-Bid-caspase-3/12 pathway. Blood 133:2222–2232.  https://doi.org/10.1182/blood-2018-12-890236CrossRefPubMedPubMedCentralGoogle Scholar
  64. Leopold JA, Walker J, Scribner AW et al (2003) Glucose-6-phosphate dehydrogenase modulates vascular endothelial growth factor-mediated angiogenesis. J Biol Chem 278:32100–32106.  https://doi.org/10.1074/jbc.M301293200CrossRefPubMedGoogle Scholar
  65. Li L, Zhao GD, Shi Z et al (2016) The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC (Review). Oncol Lett 12:3045–3050.  https://doi.org/10.3892/ol.2016.5110CrossRefPubMedPubMedCentralGoogle Scholar
  66. Li L, Shao M, Peng P et al (2017) High expression of GFAT1 predicts unfavorable prognosis in patients with hepatocellular carcinoma. Oncotarget 8:19205–19217.  https://doi.org/10.18632/oncotarget.15164CrossRefPubMedPubMedCentralGoogle Scholar
  67. Li FL, Liu JP, Bao RX et al (2018) Acetylation accumulates PFKFB3 in cytoplasm to promote glycolysis and protects cells from cisplatin-induced apoptosis. Nat Commun 9:508.  https://doi.org/10.1038/s41467-018-02950-5CrossRefPubMedPubMedCentralGoogle Scholar
  68. Liu Y, Cox SR, Morita T, Kourembanas S (1995) Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells: identification of a 5′ enhancer. Circ Res 77:638–643.  https://doi.org/10.1161/01.RES.77.3.638CrossRefPubMedGoogle Scholar
  69. Lopes-Coelho F, Nunes C, Gouveia-Fernandes S et al (2017) Monocarboxylate transporter 1 (MCT1), a tool to stratify acute myeloid leukemia (AML) patients and a vehicle to kill cancer cells. Oncotarget 8:82803–82823.  https://doi.org/10.18632/oncotarget.20294CrossRefPubMedPubMedCentralGoogle Scholar
  70. Lucena MC, Carvalho-Cruz P, Donadio JL et al (2016) Epithelial mesenchymal transition induces aberrant glycosylation through hexosamine biosynthetic pathway activation. J Biol Chem 291:12917–12929.  https://doi.org/10.1074/jbc.M116.729236CrossRefPubMedPubMedCentralGoogle Scholar
  71. Manuneedhi Cholan P, Cartland S, Kavurma M (2017) NADPH oxidases, angiogenesis, and peripheral artery disease. Antioxidants 6:56.  https://doi.org/10.3390/antiox6030056CrossRefPubMedCentralGoogle Scholar
  72. Martinive P, Defresne F, Bouzin C et al (2006) Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: implications for anticancer therapies. Cancer Res 66:11736–11744.  https://doi.org/10.1158/0008-5472.CAN-06-2056CrossRefPubMedGoogle Scholar
  73. Matsuda K, Ohga N, Hida Y et al (2010) Isolated tumor endothelial cells maintain specific character during long-term culture. Biochem Biophys Res Commun 394:947–954.  https://doi.org/10.1016/j.bbrc.2010.03.089CrossRefPubMedGoogle Scholar
  74. Miller DW, Graulich W, Karges B et al (1999) Elevated expression of endoglin, a component of the TGF-β-receptor complex, correlates with proliferation of tumor endothelial cells. Int J Cancer 81:568–572.  https://doi.org/10.1002/(SICI)1097-0215(19990517)81:4<568::AID-IJC11>3.0.CO;2-XCrossRefPubMedGoogle Scholar
  75. Miranda-Gonçalves V, Bezerra F, Costa-Almeida R et al (2017) Monocarboxylate transporter 1 is a key player in glioma-endothelial cell crosstalk. Mol Carcinog 56:2630–2642.  https://doi.org/10.1002/mc.22707CrossRefPubMedGoogle Scholar
  76. Nespereira B (2003) Vitamins C and E downregulate vascular VEGF and VEGFR-2 expression in apolipoprotein-E-deficient mice. Atherosclerosis 171:67–73.  https://doi.org/10.1016/j.atherosclerosis.2003.08.009CrossRefPubMedGoogle Scholar
  77. Ohga N, Ishikawa S, Maishi N et al (2012) Heterogeneity of tumor endothelial cells: comparison between tumor endothelial cells isolated from high- and low-metastatic tumors. Am J Pathol 180:1294–1307.  https://doi.org/10.1016/j.ajpath.2011.11.035CrossRefPubMedGoogle Scholar
  78. Okuno Y, Nakamura-Ishizu A, Otsu K et al (2012) Pathological neoangiogenesis depends on oxidative stress regulation by ATM. Nat Med 18:1208–1216.  https://doi.org/10.1038/nm.2846CrossRefPubMedGoogle Scholar
  79. Orecchioni S, Reggiani F, Talarico G et al (2015) The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells. Int J Cancer 136:E534–E544.  https://doi.org/10.1002/ijc.29193CrossRefPubMedGoogle Scholar
  80. Panieri E, Santoro MM (2015) ROS signaling and redox biology in endothelial cells. Cell Mol Life Sci 72:3281–3303.  https://doi.org/10.1007/s00018-015-1928-9CrossRefPubMedGoogle Scholar
  81. Parra-Bonilla G, Alvarez DF, Al-Mehdi A-B et al (2010) Critical role for lactate dehydrogenase a in aerobic glycolysis that sustains pulmonary microvascular endothelial cell proliferation. Am J Physiol Cell Mol Physiol 299:L513–L522.  https://doi.org/10.1152/ajplung.00274.2009CrossRefGoogle Scholar
  82. Peiró C, Romacho T, Azcutia V et al (2016) Inflammation, glucose, and vascular cell damage: the role of the pentose phosphate pathway. Cardiovasc Diabetol 15:82.  https://doi.org/10.1186/s12933-016-0397-2CrossRefPubMedPubMedCentralGoogle Scholar
  83. Peng F, Li Q, Sun JY et al (2018) PFKFB3 is involved in breast cancer proliferation, migration, invasion and angiogenesis. Int J Oncol 52:945–954.  https://doi.org/10.3892/ijo.2018.4257CrossRefPubMedGoogle Scholar
  84. Peters K, Kamp G, Berz A et al (2009) Changes in human endothelial cell energy metabolic capacities during in vitro cultivation. The role of aerobic glycolysis and proliferation. Cell Physiol Biochem 24:483–492.  https://doi.org/10.1159/000257490CrossRefPubMedGoogle Scholar
  85. Peyton KJ, Liu XM, Yu Y et al (2018) Glutaminase-1 stimulates the proliferation, migration, and survival of human endothelial cells. Biochem Pharmacol 156:204–214.  https://doi.org/10.1016/j.bcp.2018.08.032CrossRefPubMedPubMedCentralGoogle Scholar
  86. Pfeiffer T, Schuster S, Bonhoeffer S (2001) Cooperation and competition in the evolution of ATP-producing pathways. Science 292(80):504–507.  https://doi.org/10.1126/science.1058079CrossRefPubMedPubMedCentralGoogle Scholar
  87. Phoomak C, Vaeteewoottacharn K, Silsirivanit A et al (2017) High glucose levels boost the aggressiveness of highly metastatic cholangiocarcinoma cells via O-GlcNAcylation. Sci Rep 7:43842.  https://doi.org/10.1038/srep43842CrossRefPubMedPubMedCentralGoogle Scholar
  88. Potente M, Gerhardt H, Carmeliet P (2011) Basic and therapeutic aspects of angiogenesis. Cell 146:873–887.  https://doi.org/10.1016/j.cell.2011.08.039CrossRefPubMedGoogle Scholar
  89. Prieto-Bermejo R, Hernández-Hernández A (2017) The importance of NADPH oxidases and redox signaling in angiogenesis. Antioxidants 6:32.  https://doi.org/10.3390/antiox6020032CrossRefPubMedCentralGoogle Scholar
  90. Riganti C, Gazzano E, Polimeni M et al (2012) The pentose phosphate pathway: an antioxidant defense and a crossroad in tumor cell fate. Free Radic Biol Med 53:421–436.  https://doi.org/10.1016/j.freeradbiomed.2012.05.006CrossRefGoogle Scholar
  91. Rohlena J, Dong L-F, Kluckova K et al (2011) Mitochondrially targeted α-Tocopheryl succinate is antiangiogenic: potential benefit against tumor angiogenesis but caution against wound healing. Antioxid Redox Signal 15:2923–2935.  https://doi.org/10.1089/ars.2011.4192CrossRefPubMedPubMedCentralGoogle Scholar
  92. Rohlenova K, Veys K, Miranda-Santos I et al (2017) Endothelial cell metabolism in health and disease. Trends Cell Biol:1–13.  https://doi.org/10.1016/j.tcb.2017.10.010CrossRefGoogle Scholar
  93. Ruan GX, Kazlauskas A (2013) Lactate engages receptor tyrosine kinases Axl, Tie2, and vascular endothelial growth factor receptor 2 to activate phosphoinositide 3-kinase/AKT and promote angiogenesis. J Biol Chem 288:21161–21172.  https://doi.org/10.1074/jbc.M113.474619CrossRefPubMedPubMedCentralGoogle Scholar
  94. San-Millán I, Brooks GA (2017) Reexamining cancer metabolism: lactate production for carcinogenesis could be the purpose and explanation of the Warburg effect. Carcinogenesis 38:119–133.  https://doi.org/10.1093/carcin/bgw127CrossRefPubMedGoogle Scholar
  95. Santoro MM (2018) Fashioning blood vessels by ROS signalling and metabolism. Semin Cell Dev Biol 80:35–42.  https://doi.org/10.1016/j.semcdb.2017.08.002CrossRefPubMedGoogle Scholar
  96. Schoors S, De Bock K, Cantelmo AR et al (2014a) Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis. Cell Metab 19:37–48.  https://doi.org/10.1016/j.cmet.2013.11.008CrossRefPubMedGoogle Scholar
  97. Schoors S, Cantelmo AR, Georgiadou M et al (2014b) Incomplete and transitory decrease of glycolysis: a new paradigm for anti-angiogenic therapy? Cell Cycle 13:16–22.  https://doi.org/10.4161/cc.27519CrossRefPubMedGoogle Scholar
  98. Schoors S, Bruning U, Missiaen R et al (2015) Fatty acid carbon is essential for dNTP synthesis in endothelial cells. Nature 520:192–197.  https://doi.org/10.1038/nature14362CrossRefPubMedPubMedCentralGoogle Scholar
  99. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:721–732.  https://doi.org/10.1038/nrc1187CrossRefPubMedGoogle Scholar
  100. Senger DR, Galli SJ, Dvorak AM et al (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219(80):983–985.  https://doi.org/10.1126/science.6823562CrossRefGoogle Scholar
  101. Shafique E, Torina A, Reichert K et al (2017) Mitochondrial redox plays a critical role in the paradoxical effects of NAPDH oxidase-derived ROS on coronary endothelium. Cardiovasc Res 113:234–246.  https://doi.org/10.1093/cvr/cvw249CrossRefPubMedPubMedCentralGoogle Scholar
  102. Shi WK, Zhu XD, Wang CH et al (2018) PFKFB3 blockade inhibits hepatocellular carcinoma growth by impairing DNA repair through AKT article. Cell Death Dis 9:428.  https://doi.org/10.1038/s41419-018-0435-yCrossRefPubMedPubMedCentralGoogle Scholar
  103. Silva LS, Goncalves LG, Silva F et al (2015) STAT3:FOXM1 and MCT1 drive uterine cervix carcinoma fitness to a lactate-rich microenvironment. Tumor Biol 37:5385–5395.  https://doi.org/10.1007/s13277-015-4385-zCrossRefGoogle Scholar
  104. Silverstein RL, Febbraio M (2009) CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal 2.  https://doi.org/10.1126/scisignal.272re3CrossRefGoogle Scholar
  105. Slawson C, Copeland RJ, Hart GW (2010) O-GlcNAc signaling: a metabolic link between diabetes and cancer? Trends Biochem Sci 35(35):547–555.  https://doi.org/10.1016/j.tibs.2010.04.005CrossRefPubMedPubMedCentralGoogle Scholar
  106. Sliwinska PN, Alitalo K, Allen E et al (2018) Consensus guidelines for the use and interpretation of angiogenesis assays. Springer, New YorkGoogle Scholar
  107. Sonveaux P, Copetti T, de Saedeleer CJ et al (2012) Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis. PLoS One 7:e33418.  https://doi.org/10.1371/journal.pone.0033418CrossRefPubMedPubMedCentralGoogle Scholar
  108. Stacker SA, Achen MG (2013) The VEGF signaling pathway in cancer: the road ahead. Chin J Cancer 32:297–302.  https://doi.org/10.5732/cjc.012.10319CrossRefPubMedPubMedCentralGoogle Scholar
  109. Tang N, Wang L, Esko J et al (2004) Loss of HIF-1α in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 6:485–495.  https://doi.org/10.1016/j.ccr.2004.09.026CrossRefPubMedGoogle Scholar
  110. Trenti A, Tedesco S, Boscaro C et al (2017) The glycolytic enzyme PFKFB3 is involved in estrogen-mediated angiogenesis via GPER1. J Pharmacol Exp Ther 361:398–407.  https://doi.org/10.1124/jpet.116.238212CrossRefPubMedGoogle Scholar
  111. Ushio-Fukai M, Nakamura Y (2008) Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett 266:37–52.  https://doi.org/10.1016/j.canlet.2008.02.044CrossRefPubMedPubMedCentralGoogle Scholar
  112. Vasconcelos-Dos-Santos A, Loponte HFBR, Mantuano NR et al (2017) Hyperglycemia exacerbates colon cancer malignancy through hexosamine biosynthetic pathway. Oncogene 6:e306.  https://doi.org/10.1038/oncsis.2017.2CrossRefGoogle Scholar
  113. Végran F, Boidot R, Michiels C et al (2011) Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-kB/IL-8 pathway that drives tumor angiogenesis. Cancer Res 71:2550–2560.  https://doi.org/10.1158/0008-5472.CAN-10-2828CrossRefPubMedGoogle Scholar
  114. Vizán P, Sánchez-Tena S, Alcarraz-Vizán G et al (2009) Characterization of the metabolic changes underlying growth factor angiogenic activation: identification of new potential therapeutic targets. Carcinogenesis 30:946–952.  https://doi.org/10.1093/carcin/bgp083CrossRefPubMedGoogle Scholar
  115. Wang CC, Xu H, Man GCW et al (2013) Prodrug of green tea epigallocatechin-3-gallate (Pro-EGCG) as a potent anti-angiogenesis agent for endometriosis in mice. Angiogenesis 16:59–69.  https://doi.org/10.1007/s10456-012-9299-4CrossRefPubMedGoogle Scholar
  116. Wang J, Man GCW, Chan TH et al (2018) A prodrug of green tea polyphenol (–)-epigallocatechin-3-gallate (Pro-EGCG) serves as a novel angiogenesis inhibitor in endometrial cancer. Cancer Lett 412:10–20.  https://doi.org/10.1016/j.canlet.2017.09.054CrossRefPubMedGoogle Scholar
  117. Wei R, Mao L, Xu P et al (2018) Suppressing glucose metabolism with epigallocatechin-3-gallate (EGCG) reduces breast cancer cell growth in preclinical models. Food Funct 9:5682–5696.  https://doi.org/10.1039/c8fo01397gCrossRefPubMedGoogle Scholar
  118. Weigand JE, Boeckel J-N, Gellert P, Dimmeler S (2012) Hypoxia-induced alternative splicing in endothelial cells. PLoS One 7:e42697.  https://doi.org/10.1371/journal.pone.0042697CrossRefPubMedPubMedCentralGoogle Scholar
  119. Wenes M, Shang M, Di Matteo M et al (2016) Macrophage metabolism controls tumor blood vessel morphogenesis and metastasis. Cell Metab 24:701–715.  https://doi.org/10.1016/j.cmet.2016.09.008CrossRefPubMedPubMedCentralGoogle Scholar
  120. West XZ, Malinin NL, Merkulova AA et al (2010) Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands. Nature 467:972–976.  https://doi.org/10.1038/nature09421CrossRefPubMedPubMedCentralGoogle Scholar
  121. Wilting J, Chao TI (2015) Integrated vascular anatomy. In: PanVascular medicine, 2nd edn. Springer, New York, pp 193–241CrossRefGoogle Scholar
  122. Wong BW, Marsch E, Treps L et al (2017) Endothelial cell metabolism in health and disease : impact of hypoxia. EMBO J 36:1–17.  https://doi.org/10.15252/embj.201696150CrossRefGoogle Scholar
  123. Wu D, Huang R-T, Hamanaka RB et al (2017) HIF-1α is required for disturbed flow-induced metabolic reprogramming in human and porcine vascular endothelium. elife 6:1–26.  https://doi.org/10.7554/eLife.25217CrossRefGoogle Scholar
  124. Xu Y, An X, Guo X et al (2014) Endothelial PFKFB3 plays a critical role in angiogenesis. Arterioscler Thromb Vasc Biol 34:1231–1239.  https://doi.org/10.1161/ATVBAHA.113.303041CrossRefPubMedPubMedCentralGoogle Scholar
  125. Yamamoto K, Ohga N, Hida Y et al (2012) Biglycan is a specific marker and an autocrine angiogenic factor of tumour endothelial cells. Br J Cancer 106:1214–1223.  https://doi.org/10.1038/bjc.2012.59CrossRefPubMedPubMedCentralGoogle Scholar
  126. Yeh W-L, Lin C-J, Fu W-M (2007) Enhancement of glucose transporter expression of brain endothelial cells by vascular endothelial growth factor derived from glioma exposed to hypoxia. Mol Pharmacol 73:170–177.  https://doi.org/10.1124/mol.107.038851CrossRefPubMedGoogle Scholar
  127. Yu P, Wilhelm K, Dubrac A et al (2017) FGF-dependent metabolic control of vascular development. Nature 545:224–228.  https://doi.org/10.1038/nature22322CrossRefPubMedPubMedCentralGoogle Scholar
  128. Zang Z, Apse K, Pang J, Stanton RC (2000) High glucose inhibits glucose-6-phosphate dehydrogenase via cAMP in aortic endothelial cells. J Biol Chem 275:40042–40047.  https://doi.org/10.1074/jbc.M007505200CrossRefGoogle Scholar
  129. Zetter BR (2008) The scientific contributions of M. Judah Folkman to cancer research. Nat Rev Cancer 8:647–654.  https://doi.org/10.1038/nrc2458CrossRefPubMedGoogle Scholar
  130. Zhang N, Zhu T, Yu K et al (2019) Elevation of O-GlcNAc and GFAT expression by nicotine exposure promotes epithelial-mesenchymal transition and invasion in breast cancer cells. Cell Death Dis 10:343.  https://doi.org/10.1038/s41419-019-1577-2CrossRefPubMedPubMedCentralGoogle Scholar
  131. Zhong Q, Li X, Nong Q et al (2017) Metabolic profiling in association with vascular endothelial cell dysfunction following non-toxic cadmium exposure. Int J Mol Sci 18:E1905.  https://doi.org/10.3390/ijms18091905CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Filipa Lopes-Coelho
    • 1
    • 2
  • Filipa Martins
    • 1
    • 2
  • Jacinta Serpa
    • 1
    • 2
    Email author
  1. 1.CEDOC, Chronic Diseases Research Centre, NOVA Medical School | Faculdade de Ciências MédicasUniversidade NOVA de LisboaLisbonPortugal
  2. 2.Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG)LisbonPortugal

Personalised recommendations